STAAR Surgical Company (STAA)

Market Cap	1.54B
Revenue (ttm)	310.19M
Net Income (ttm)	19.44M
Shares Out	48.82M
EPS (ttm)	0.38
PE Ratio	84.13
Forward PE	31.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190,227
Open	32.05
Previous Close	31.97
Day's Range	31.58 - 33.05
52-Week Range	31.00 - 81.81
Beta	1.05
Analysts	Buy
Price Target	49.83 (+57.82%)
Earnings Date	Nov 1, 2023

About STAA

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the compan...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 882
• Stock Exchange: NASDAQ
• Ticker Symbol: STAA

Financial Performance

In 2022, STAA's revenue was $284.39 million, an increase of 23.40% compared to the previous year's $230.47 million. Earnings were $38.76 million, an increase of 58.18%.

Analyst Forecast

According to 9 analysts, the average rating for STAA stock is "Buy." The 12-month stock price forecast is $49.83, which is an increase of 57.82% from the latest price.

Price Target

$49.83

(57.82% upside)

Analyst Consensus: Buy